Navigation Links
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Announces FDA Filings for Paliperidone Palmitate and INVEGA(R)
Date:2/6/2009

TITUSVILLE, N.J., Feb. 6 /PRNewswire/ -- Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD) today announced that the company has submitted multiple applications to the U.S. Food and Drug Administration (FDA) which, if approved, would broaden treatment options for patients diagnosed with schizophrenia or schizoaffective disorder.

Earlier this week, the company submitted its response to the FDA complete response letter for paliperidone palmitate, received in August 2008. Paliperidone palmitate is an investigational once-monthly atypical antipsychotic injection which, if approved, will be indicated for the acute and maintenance treatment of schizophrenia.

The company also submitted two supplemental new drug applications (sNDAs) to the FDA requesting approval for the use of INVEGA tablets for the treatment of schizoaffective disorder as monotherapy and for use in combination with antidepressants and/or mood stabilizers. The sNDA submissions include data from two international, 6-week double-blind placebo-controlled studies that evaluated the efficacy and safety of INVEGA in patients with schizoaffective disorder. If approved by the FDA, INVEGA would be the only medication indicated to treat the condition.

Patients with schizoaffective disorder experience the psychotic symptoms of schizophrenia, such as hallucinations or delusions, as well as mania and/or depression. Because of the similarity in symptoms, schizoaffective disorder is sometimes misdiagnosed as schizophrenia or bipolar disorder. For patients who frequently use mental health services, schizophrenia and schizoaffective disorder may account for approximately 32% and 24% of cases respectively.(i)

INVEGA, an atypical antipsychotic medication, was first approved in the U.S. in December 2006 and is marketed by Janssen. It is approved for the acute and maintenance treatment of schizophrenia in the U.S. an
'/>"/>

SOURCE Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD)
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Johnson & Johnson to Provide Webcast Presentation of Tapentadol Phase 3 Clinical Data Presented at American Pain Societys Annual Meeting
2. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
3. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
6. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
7. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
8. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
9. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... 17, 2013  Atossa Genetics, Inc. (NASDAQ: ATOS ... Kyle Guse , Chief Financial Officer & General Counsel, ... on Thursday, May 30, 2013, in New York ... The Company,s presentation is scheduled to begin at 3:30 ... To access the webcast, go to www.atossagenetics.com . ...
(Date:5/17/2013)... BEIJING , May 17, 2013 Sinovac Biotech ... vaccines in China , today announced that ... quarter ended March 31, 2013, before market on Tuesday, May ... Tuesday, May 28, 2013, at 8:00 a.m. EDT (May 28, ... Company,s financial results and provide an update on recent corporate ...
(Date:5/16/2013)... CHICAGO, Ill. and MECHELEN, Belgium ... (Euronext: GLPG) and AbbVie (NYSE: ABBV ) ... collaboration to include Crohn,s disease.  Galapagos will fund and ... is designed to facilitate rapid progression into Phase 3.  ... 2015, AbbVie will pay Galapagos $50 million.  The terms ...
Breaking Medicine Technology:Atossa Genetics to Present at the Second Annual Marcum LLP MicroCap Conference 2Atossa Genetics to Present at the Second Annual Marcum LLP MicroCap Conference 3Sinovac to Host Conference Call to Report First Quarter 2013 Unaudited Financial Results 2Sinovac to Host Conference Call to Report First Quarter 2013 Unaudited Financial Results 3AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 2AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 3AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 4AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 5AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 6
... Decline in Global Measles Deaths, Joint News Release: ... and WASHINGTON, Nov. 29, Measles deaths in Africa fell ... 396,000 to 36,000, reaching the,United Nations 2010 goal to ... spectacular gains achieved in Africa helped generate a strong,decline ...
... Nov. 29 AIDS Action Council,joins organizations and individuals ... 20th annual World AIDS Day, December 1, 2007. Since ... awareness,about the HIV/AIDS pandemic and to reinvigorate global, national, ... and 2008 theme of World AIDS Day is leadership. ...
Cached Medicine Technology:Measles Deaths in Africa Plunge by 91% 2Measles Deaths in Africa Plunge by 91% 3Measles Deaths in Africa Plunge by 91% 4AIDS Action Council Statement on World AIDS Day 2007: Leadership Needed for a National Strategy to Stop the AIDS Epidemic 2
(Date:5/19/2013)... SUNDAY, May 19 (HealthDay News) -- Although spring arrived ... the summer allergy season will still be strong, according ... at Birmingham. Dr. Richard Waguespack, clinical professor in ... often results in a robust summer allergy season. However, ... as sneezing, wheezing and coughing, he added. "Tree ...
(Date:5/19/2013)... St. Louis, MO (PRWEB) May 19, 2013 ... Member Conference, May 19-22, 2013, at the Walt Disney ... the latest trends in supply chain innovation, care delivery ... a much different dynamic in all healthcare markets, ... necessary part of the conversation,” said Todd Ebert, Amerinet ...
(Date:5/19/2013)... May 19, 2013 Actos lawsuit ... litigation now underway in U.S. District Court, Western District ... dated May 3rd, the Court has modified the litigation’s ... eight cases rather than four. The next Status Conference ... May 23rd. (In re: Actos Product Liability Litigation, MDL ...
(Date:5/19/2013)... May 19, 2013 According to ... Analysis and Forecast (2013 – 2018): By Applications ... Industrial)); Technology (CCD, CMOS, Contact IS, Infrared, X-Ray) ... image sensor market was $8.00 billion in 2012 ... 2018, at an estimated CAGR of 3.84% from ...
(Date:5/19/2013)... Fat Burning Furnace developed by Rob ... people with fat burning diet plans, training ... Burning Furnace package, people will receive the Fat Burning ... quickly. The Fat Burning Furnace manual includes fat loss ... muscle mass. In addition, this book covers step-by-step instructions, ...
Breaking Medicine News(10 mins):Health News:Managing Seasonal Allergies 2Health News:Healthcare Leaders Gather at 2013 Amerinet Member Conference to Share New Ways to Reduce Costs and Enhance Care Delivery 2Health News:Actos Lawyers at Bernstein Liebhard LLP Note Issuance of New Case Management Order in Federal Actos Bladder Cancer Litigation 2Health News:Actos Lawyers at Bernstein Liebhard LLP Note Issuance of New Case Management Order in Federal Actos Bladder Cancer Litigation 3Health News:Image Sensors Market to Reach $10.75 Billion by 2018 at a CAGR of 3.84% - New Report by MarketandMarkets 2Health News:Image Sensors Market to Reach $10.75 Billion by 2018 at a CAGR of 3.84% - New Report by MarketandMarkets 3Health News:Fat Burning Diet | How “Fat Burning Furnace” Helps People Lose Their Weight Naturally And Fast – V-kool 2
... 19 (HealthDay News) -- Scientists say they,ve identified the first ... known as plaque psoriasis. "We have searched for almost ... psoriasis," study senior author Anne Bowcock, professor of genetics at ... a university news release. "Individually, the rare mutations we have ...
... Brophy Marcus HealthDay Reporter , THURSDAY, April 19 ... may want to let it go. A new study suggests ... happier years later in life. Researchers from the University ... 60-somethings to see how it affected their emotional health. ...
... Australia have discovered that salicylate, the active ingredient in ... (AMP-activated protein kinase), a key player in regulating cell ... cellular fuel-gauge is switched on by exercise and the ... scientists at McMaster University, the University of Dundee and ...
... of pregnant women and newborns for the presence of ... according to a Vanderbilt study now available online and ... study,s senior author, Buddy Creech, M.D., MPH, assistant professor ... carrying MRSA may risk transmitting an infection to their ...
... HealthDay Reporter , THURSDAY, April 19 (HealthDay News) ... been diagnosed with early-onset Alzheimer,s disease, celebrated women,s basketball coach ... University of Tennessee Lady Vols team. "I,ve loved being ... recognize that the time has come to move into the ...
... , THURSDAY, April 19 (HealthDay News) -- Most people know ... cancer diagnosis low: Don,t smoke, eat healthy, exercise and get ... choices, and a new report suggests that lawmakers and private ... easier ones to make. ...
Cached Medicine News:Health News:Gene Behind Psoriasis Identified, Researchers Say 2Health News:'No Regrets' Outlook May Make for Sunnier Old Age 2Health News:'No Regrets' Outlook May Make for Sunnier Old Age 3Health News:McMaster researchers find potential for new uses of old drug 2Health News:Concerns about MRSA for expectant mothers may be unfounded 2Health News:Basketball Legend Pat Summitt Leaving as Tennessee Women's Coach 2Health News:Basketball Legend Pat Summitt Leaving as Tennessee Women's Coach 3Health News:Basketball Legend Pat Summitt Leaving as Tennessee Women's Coach 4Health News:Healthy Lifestyle Choices Could Cut Cancer Rates: Report 2Health News:Healthy Lifestyle Choices Could Cut Cancer Rates: Report 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: